Biomea Fusion’s Icovamenib Achieves 1.5% HbA1c Reduction After 52 Weeks
Biomea Fusion reported positive 52-week outcomes from its Phase II COVALENT-111 trial of icovamenib in type 2 diabetes, showing a 1.5% mean HbA1c reduction (p=0.01) in severe insulin-deficient patients and a 24% C-peptide increase. The compound maintained a favorable safety profile with no serious drug-related adverse events.
1. Phase II COVALENT-111 Study Design
COVALENT-111 was a double-blind, randomized, placebo-controlled trial enrolling 267 evaluable adults with T2D diagnosed within seven years, HbA1c between 7.0% and 10.5%, and BMI of 25–40 kg/m². Participants received icovamenib in three regimens: Arm A (100 mg QD for 8 weeks), Arm B (100 mg QD for 12 weeks), and Arm C (100 mg QD for 8 weeks followed by 100 mg BID for 4 weeks), all on top of standard lifestyle and antidiabetic therapies.
2. Efficacy in Severe Insulin-Deficient Patients
In the prespecified severe insulin-deficient subgroup (n=10), icovamenib delivered a durable HbA1c reduction reaching 1.2% at Week 52 versus placebo, with Arm B (n=6) achieving a 1.5% mean drop (p=0.01). C-peptide index rose 24% from baseline, indicating enhanced endogenous insulin secretion, while a GLP-1 therapy subgroup (n=12) also saw a 1.2% HbA1c decline (p=0.05) and a 35% C-peptide increase.
3. Safety Profile and Upcoming Milestones
Icovamenib was well tolerated over 52 weeks with no treatment-related serious adverse events or discontinuations. Biomea Fusion plans two new Phase II T2D studies targeting responsive subgroups, with Type 1 diabetes follow-up data from COVALENT-112 due in Q2 2026 and 26-week readouts for COVALENT-211 and COVALENT-212 expected in Q4 2026.